Approval · Notice of Compliance 25817 · 2021
SYNAGIS: Notice of Compliance 25817
Issued May 6, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25817
- Date
- May 6, 2021
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SYNAGIS | Not yet assigned | — |
Medicinal ingredients
- PALIVIZUMAB 100 MG per ML